semaglutide and masld Pharmacotherapy: Current Standards, Emerging Treatments, Practical Guidance for Indian Physicians Impact of Fibrotic Metabolic Dysfunction–Associated

When combined with clinical markers (weight loss trajectory, GI tolerance, metabolic improvements), genetic insights can help your provider design a more personalized dose plan rather than following a one-size-fits-all escalation protocol

Such multifaceted mechanisms enhance GPSs potential as an antidiabetic agent

Boehringer Ingelheim is expected to be the third player in this space with their launch of survodutide in the first half of 2027

At the pancreas, it potentiates glucose-stimulated insulin secretion while suppressing glucagon release, thereby lowering circulating glucose concentrations

The incidence of AF in our study was close to a previous cohort study (39 per 10,000 patient-years vs 32 per 10,000 patient-years) [26]